| Market Cap | 8.64M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -18.15M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -40.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -68.00% |
| Dividend | N/A | Price/Book | 3.25 | EPS next 5Y | - | 52W High Chg | -94.00% |
| Recommedations | - | Quick Ratio | 1.35 | Shares Outstanding | 7.78M | 52W Low Chg | 2.00% |
| Insider Own | - | ROA | -258.30% | Shares Float | 6.81M | Beta | - |
| Inst Own | 0.78% | ROE | -975.03% | Shares Shorted/Prior | 637.72K/552.33K | Price | 0.59 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 751,298 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 191,063 | Change | -7.28% |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
| HC Wainwright & Co. | Buy | Dec 4, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Rome Zachary | Director Director | Jan 29 | Sell | 0.48 | 811 | 389 | 15,148 | 01/31/24 |
| LaRochelle Karen | Director Director | Jan 29 | Sell | 0.48 | 78 | 37 | 2,829 | 01/31/24 |
| Coelho John F | Director Director | Jan 29 | Sell | 0.48 | 27 | 13 | 4,615 | 01/31/24 |
| Weisman Howard J. | Chief Executive Offi.. Chief Executive Officer | Jan 29 | Sell | 0.47 | 372 | 175 | 37,675 | 01/31/24 |
| Rome Zachary | Director Director | Oct 27 | Sell | 0.1848 | 16,301 | 3,012 | 277,390 | 10/30/23 |
| Derby Michael | 10% Owner 10% Owner | Oct 27 | Sell | 0.1897 | 9,175 | 1,740 | 439,171 | 10/30/23 |
| Coelho John F | Director Director | Oct 27 | Sell | 0.1895 | 570 | 108 | 79,090 | 10/30/23 |
| LaRochelle Karen | Director Director | Oct 27 | Sell | 0.189 | 1,679 | 317 | 49,994 | 10/30/23 |
| Weisman Howard J. | Chairman and CEO Chairman and CEO | Oct 27 | Sell | 0.1894 | 8,049 | 1,524 | 649,549 | 10/30/23 |
| Weisman Howard J. | Chief Executive Offi.. Chief Executive Officer | Mar 08 | Sell | 1.45 | 35,892 | 52,043 | 541,633 | 03/09/23 |
| Rome Zachary | Chief Operating Offi.. Chief Operating Officer | Mar 08 | Sell | 1.46 | 33,405 | 48,771 | 288,452 | 03/09/23 |
| Derby Michael | Executive Chairman Executive Chairman | Mar 09 | Sell | 1.43 | 2,143 | 3,064 | 324,430 | 03/09/23 |
| LaRochelle Karen | Director Director | Mar 09 | Sell | 1.48 | 335 | 496 | 42,415 | 03/09/23 |
| Coelho John F | Director Director | Mar 09 | Sell | 1.48 | 130 | 192 | 67,235 | 03/09/23 |
| Weisman Howard J. | Chief Executive Offi.. Chief Executive Officer | Mar 06 | Sell | 1.63 | 37,140 | 60,538 | 577,525 | 03/07/23 |
| Rome Zachary | Chief Operating Offi.. Chief Operating Officer | Mar 06 | Sell | 1.63 | 36,992 | 60,297 | 321,857 | 03/07/23 |
| Derby Michael | Executive Chairman Executive Chairman | Mar 06 | Sell | 1.64 | 28,962 | 47,498 | 326,573 | 03/07/23 |
| Coelho John F | Director Director | Mar 02 | Sell | 1.93 | 3,013 | 5,815 | 67,365 | 03/03/23 |
| LaRochelle Karen | Director Director | Mar 02 | Sell | 1.92 | 8,833 | 16,959 | 42,750 | 03/03/23 |
| Weisman Howard J. | Chief Executive Offi.. Chief Executive Officer | Mar 02 | Sell | 1.92 | 27,002 | 51,844 | 614,665 | 03/03/23 |
| Rome Zachary | Chief Operating Offi.. Chief Operating Officer | Mar 02 | Sell | 1.92 | 26,151 | 50,210 | 358,849 | 03/03/23 |
| Derby Michael | Executive Chairman Executive Chairman | Mar 02 | Sell | 1.92 | 29,465 | 56,573 | 355,535 | 03/03/23 |